FE-201836 is under clinical development by Ferring International Center and currently in Phase II for Nocturia. According to GlobalData, Phase II drugs for Nocturia have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FE-201836’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FE-201836 is under development for the treatment of nocturia due to nocturnal polyuria. The drug candidate is a peptide and administered through the oral route.
Ferring International Center overview
Ferring International Center (Ferring), a subsidiary of Ferring Holding SA research, develops and markets pharmaceutical products. The company offers products in the fields of reproductive health, endocrinology, gastroenterology, urology, and orthopedics. Its major products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; and Firmagon (degarelix) for prostate cancer. Its pipeline products encompass rHCG for Triggering FFM and rFSH for male infertility for infertility; FE 202767 for Lactation; RBX2660 enema for difficile infection among others. It has production facilities in Europe, Asia, and a manufacturing site in the US. Ferring is headquartered in Saint-Prex, Switzerland.
For a complete picture of FE-201836’s drug-specific PTSR and LoA scores, buy the report here.